A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

November 9, 2023

Primary Completion Date

May 13, 2024

Study Completion Date

May 13, 2024

Conditions
Advanced Solid Tumors
Interventions
DRUG

BMS-986466

Specified dose on specified days

DRUG

Adagrasib

Specified dose on specified days

DRUG

Cetuximab

Specified dose on specified days

Trial Locations (9)

2145

Local Institution - 0053, Westmead

30607

Local Institution - 0040, Athens

59037

Local Institution - 0020, Lille

90067

Local Institution - 0047, Los Angeles

4941492

Local Institution - 0082, Petah Tikva

6423906

Local Institution - 0081, Tel Aviv

07601

Local Institution - 0025, Hackensack

07960

Local Institution - 0008, Morristown

00029

Local Institution - 0083, Helsinki

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY